• DAYBUE 2024 net sales in the US reached US$348.4 million, up 97% from 2023
• Q4 2024 net sales of US$96.7 million was a record quarter since launch in April 2023
• Acadia provided 2025 US net sales guidance of US$380-405 million

Neuren Pharmaceuticals (ASX: NEU) today reported highlights from the Q4 and full year 2024 earnings announcement and conference call of its partner Acadia Pharmaceuticals (Nasdaq: ACAD). Acadia announced 2024 net sales of DAYBUE™ (trofinetide) in the United States of US$348.4 million, up 97% from 2023, and towards the top of its previous guidance range of US$340-350 million. Q4 net sales of US$96.7 million was a record quarter of sales since launch in April 2023. With 70% of the 5,500 to 5,800 diagnosed Rett patients yet to try DAYBUE, there is substantial potential for growth in the US. Acadia is implementing initiatives to accelerate adoption, in particular among patients treated outside the Rett syndrome Centers of Excellence. Acadia is expanding its field force by ~30%, optimizing patient support, launching branded Direct-to-Consumer campaigns to showcase DAYBUE benefits and utilizing a range of communication channels to bring DAYBUE clinical data to life. Acadia provided guidance for full-year US only net sales in 2025 of between US$380 million and US$405 million. Outside the US, first sales in Canada are anticipated in Q3 2025, pending price negotiations. Acadia is also expecting initial revenues from managed access programs in certain EU countries this year, while continuing to build EU leadership and launch teams anticipating approval of the marketing application in Q1 2026.

Acadia provided guidance for full-year US only net sales of DAYBUE in 2025 of between US$380 million and US$405 million.

With 70% of the 5,500 to 5,800 diagnosed Rett patients yet to try DAYBUE, there is substantial potential for growth in the US. Acadia is implementing initiatives to accelerate adoption, in particular among patients treated outside the Rett syndrome Centers of Excellence.